Gene therapy research in Asia

Gene Therapy

Volumn 24, Issue 9, 2017, Pages 572-577

  Deng, H X ^a   Wang, Y ^a   Ding, Q R ^b   Li, D L ^c   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASIA; CANCER GENE THERAPY; CARDIOVASCULAR DISEASE; CHINA; CLINICAL TRIAL (TOPIC); GENE THERAPY; GENE VECTOR; HUMAN; INFECTION; MONOGENIC DISORDER; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; MEDICAL RESEARCH; STATISTICS AND NUMERICAL DATA;

ASIA; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; GENETIC THERAPY;

EID: 85032486259     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2017.62     Document Type: Review

References (77)

1. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-733.
2. Husain SR, Han J, Au P, Shannon K, Puri RK. Gene therapy for cancer: regulatory considerations for approval. Cancer Gene Ther 2015; 22: 554-563.
3. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014; 370: 901-910.
4. Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, Workman C et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 2009; 15: 285-292.
5. Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science (New York, NY) 2013; 341: 1233151.
6. Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16: 198-204.
7. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-158.
8. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (New York, NY) 2003; 302: 415-419.
9. McCormack MP, Rabbitts TH. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2004; 350: 913-922.
10. Fischer A, Abina SH, Thrasher A, von Kalle C, Cavazzana-Calvo M. LMO2 and gene therapy for severe combined immunodeficiency. N Engl J Med 2004; 350: 2526-2527; author reply 2526-7.
11. Naldini L. Medicine. A comeback for gene therapy. Science (New York, NY) 2009; 326: 805-806.
12. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science (New York, NY) 2013; 342: 1432-1433.
13. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 16: 1016-1027.
14. Liang M. Clinical development of oncolytic viruses in China. Curr Pharm Biotechnol 2012; 13: 1852-1857.
15. Yla-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther 2012; 20: 1831-1832.
16. Chervyakov YV, Staroverov IN, Vlasenko ON, Bozo IY, Isaev AA, Deev RV. [Five-year results of treating patients with chronic lower limb ischaemia by means of gene engineering]. Angiol Vasc Surg 2016; 22: 38-44.
17. Schimmer J, Breazzano S. Investor outlook: rising from the ashes; GSK's European approval of strimvelis for ADA-SCID. Hum Gene Ther Clin Dev 2016; 27: 57-61.
18. Adams L. Motor neuron disease: Nusinersen potentially effective in SMA. Nat Rev Neurol 2017; 13: 66.
19. Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet (Lond, Engl) 2016; 388: 3017-3026.
20. Cyranoski D. Chinese scientists to pioneer first human CRISPR trial. Nature 2016; 535: 476-477.
21. Kumar SR, Markusic DM, Biswas M, High KA, Herzog RW. Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev 2016; 3: 16034.
22. Saadatpour Z, Bjorklund G, Chirumbolo S, Alimohammadi M, Ehsani H, Ebrahiminejad H et al. Molecular imaging and cancer gene therapy. Cancer Gene Ther; epub ahead of print 18 November 2016; doi:10.1038/cgt.2016.62.
23. Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 2014; 25: 304-317.
24. Li Y, Li B, Li CJ, Li LJ. Key points of basic theories and clinical practice in rAd-p53 (Gendicine ) gene therapy for solid malignant tumors. Expert Opin Biol Ther 2015; 15: 437-454.
25. O'Shea CC, Soria C, Bagus B, McCormick F. Heat shock phenocopies E1B-55 K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 2005; 8: 61-74.
26. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6: 611-623.
27. Rojas-Martinez A, Manzanera AG, Sukin SW, Esteban-Maria J, Gonzalez-Guerrero JF, Gomez-Guerra L et al. Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer. Cancer Gene Ther 2013; 20: 642-649.
28. Karjoo Z, Chen X, Hatefi A. Progress and problems with the use of suicide genes for targeted cancer therapy. Adv Drug Deliv Rev 2016; 99 (Pt A): 113-128.
29. Li N, Zhou J, Weng D, Zhang C, Li L, Wang B et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2007; 13: 5847-5854.
30. Xu F, Li S, Li XL, Guo Y, Zou BY, Xu R et al. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors. Cancer Gene Ther 2009; 16: 723-730.
31. Ji N, Weng D, Liu C, Gu Z, Chen S, Guo Y et al. Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma. Oncotarget 2016; 7: 4369-4378.
32. Mi Y, Li Y, Long Y. [Antitumor effects of radioiodine labeled KH901 on nude mice bearing hepatoma]. J Biomed Eng 2010; 27: 389-394.
33. Mi YX, Li YC, Long YH. Imaging of radioiodine-labeled KH901, a tumor-specific oncolytic recombinant adenovirus, in nude mice with human hepatocellular carcinoma. Nucl Med Commun 2010; 31: 405-410.
34. Chang J, Zhao X, Wu X, Guo Y, Guo H, Cao J et al. A phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biol Ther 2009; 8: 676-682.
35. Gao YD, Chen GL, Guo PD, Yang XL. [Study on the application effect of Once Vex (GM)(-)(CSF) and adriamycin in the interventional therapy of malignant tumor in clinical curative effect]. Zhonghua Yi Xue Za Zhi 2016; 96: 2173-2175.
36. Wang L, Yao B, Li Q, Mei K, Xu JR, Li HX et al. Gene therapy with recombinant adenovirus encoding endostatin encapsulated in cationic liposome in coxsackievirus and adenovirus receptor-deficient colon carcinoma murine models. Hum Gene Ther 2011; 22: 1061-1069.
37. Ye W, Liu R, Pan C, Jiang W, Zhang L, Guan Z et al. Multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma. Mol Ther 2014; 22: 1221-1229.
38. June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. Sci Transl Med 2015; 7: 280ps7.
39. Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 2016; 375: 2561-2569.
40. Zhang H, Ye ZL, Yuan ZG, Luo ZQ, Jin HJ, Qian QJ. New strategies for the treatment of solid tumors with CAR-T cells. Int J Biol Sci 2016; 12: 718-729.
41. Beatty GL, O'Hara M. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps. Pharmacol Ther 2016; 166: 30-39.
42. Wang QS, Wang Y, Lv HY, Han QW, Fan H, Guo B et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther 2015; 23: 184-191.
43. Dai H, Zhang W, Li X, Han Q, Guo Y, Zhang Y et al. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology 2015; 4: e1027469.
44. Wang Y, Zhang WY, Han QW, Liu Y, Dai HR, Guo YL et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol 2014; 155: 160-175.
45. Feng KC, Guo YL, Liu Y, Dai HR, Wang Y, Lv HY et al. Cocktail treatment with EGFRspecific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol 2017; 10: 4.
46. Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers. Mol Ther 2017; 25: 1248-1258.
47. Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol 2015; 33: 102-106.
48. Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 2014; 32: 551-553.
49. Yonemitsu Y, Matsumoto T, Itoh H, Okazaki J, Uchiyama M, Yoshida K et al. DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther 2013; 21: 707-714.
50. Matsumoto T, Tanaka M, Yoshiya K, Yoshiga R, Matsubara Y, Horiuchi-Yoshida K et al. Improved quality of life in patients with no-option critical limb ischemia undergoing gene therapy with DVC1-0101. Sci Rep 2016; 6: 30035.
51. Liu J, Wu P, Wang H, Wang Y, Du Y, Cheng W et al. Necroptosis induced by Ad-HGF activates endogenous C-Kit+ cardiac stem cells and promotes cardiomyocyte proliferation and angiogenesis in the infarcted aged heart. Cell Physiol Biochem 2016; 40: 847-860.
52. Yang ZJ, Zhang YR, Chen B, Zhang SL, Jia EZ, Wang LS et al. Phase I clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease. Mol Biol Rep 2009; 36: 1323-1329.
53. Liu J, Wu P, Wang Y, Du Y, N A, Liu S et al. Ad-HGF improves the cardiac remodeling of rat following myocardial infarction by upregulating autophagy and necroptosis and inhibiting apoptosis. Am J Transl Res 2016; 8: 4605-4627.
54. Yang ZJ, Chen B, Sheng Z, Zhang DG, Jia EZ, Wang W et al. Improvement of heart function in postinfarct heart failure swine models after hepatocyte growth factor gene transfer: comparison of low-, medium-and high-dose groups. Mol Biol Rep 2010; 37: 2075-2081.
55. Onodera M, Ariga T, Kawamura N, Kobayashi I, Ohtsu M, Yamada M et al. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood 1998; 91: 30-36.
56. Qiu X, Lu D, Zhou J, Wang J, Yang J, Meng P et al. Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients. Chinese Med J 1996; 109: 832-839.
57. Sessa M, Lorioli L, Fumagalli F, Acquati S, Redaelli D, Baldoli C et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet (Lond, Engl) 2016; 388: 476-487.
58. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science (New York, NY) 2009; 326: 818-823.
59. Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, Starr P, Larson P et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther 2012; 23: 377-381.
60. Valdes P, Schneider BL. Gene therapy: a promising approach for neuroprotection in Parkinson's disease? Front Neuroanat 2016; 10: 123.
61. Kalia LV, Lang AE. Parkinson's disease. Lancet (Lond, Engl) 2015; 386: 896-912.
62. Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet (Lond, Engl) 2014; 383: 1138-1146.
63. Hwu WL, Muramatsu S, Tseng SH, Tzen KY, Lee NC, Chien YH et al. Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci Transl Med 2012; 4: 134ra61.
64. Johnston R. Gene therapy to cure HIV: where to from here? AIDS Patient Care STDs 2016; 30: 531-533.
65. Kim CY, Kang ES, Kim SB, Kim HE, Choi JH, Lee DS et al. Increased in vivo immunological potency of HB-110, a novel therapeutic HBV DNA vaccine, by electroporation. Exp Mol Med 2008; 40: 669-676.
66. Yoon SK, Seo YB, Im SJ, Bae SH, Song MJ, You CR et al. Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. Liver Int 2015; 35: 805-815.
67. Razi Soofiyani S, Baradaran B, Lotfipour F, Kazemi T, Mohammadnejad L. Gene therapy, early promises, subsequent problems, and recent breakthroughs. Adv Pharm Bull 2013; 3: 249-255.
68. Naldini L. Gene therapy returns to centre stage. Nature 2015; 526: 351-360.
69. Tabebordbar M, Zhu K, Cheng JK, Chew WL, Widrick JJ, Yan WX et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science (New York, NY) 2016; 351: 407-411.
70. Long C, Amoasii L, Mireault AA, McAnally JR, Li H, Sanchez-Ortiz E et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science (New York, NY) 2016; 351: 400-403.
71. Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Castellanos Rivera RM et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science (New York, NY) 2016; 351: 403-407.
72. Guan Y, Ma Y, Li Q, Sun Z, Ma L, Wu L et al. CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse. EMBO Mol Med 2016; 8: 477-488.
73. Sciences NAoMedicine NAoNational Academies of Sciences E, Medicine. Human Genome Editing: Science, Ethics, and Governance. The National Academies Press: Washington, DC, 2017.
74. Williams DA. Broadening the indications for hematopoietic stem cell genetic therapies. Cell Stem Cell 2013; 13: 263-264.
75. Hacein-Bey-Abina S, Pai SY, Gaspar HB, Armant M, Berry CC, Blanche S et al. A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med 2014; 371: 1407-1417.
76. Cicalese MP, Aiuti A. Clinical applications of gene therapy for primary immunodeficiencies. Hum Gene Ther 2015; 26: 210-219.
77. Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Diez IA, Dewey RA et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010; 363: 1918-1927.